VXRT
Vaxart, Inc.
Price Chart
Latest Quote
$0.60
-0.02 (-3.23%)
Current Price
| Previous Close | $0.62 |
| Open | $0.60 |
| Day High | $0.62 |
| Day Low | $0.58 |
| Volume | 334,877 |
Stock Information
| Shares Outstanding | 242.04M |
| Total Debt | $12.20M |
| Cash Equivalents | $61.02M |
| Revenue | $255.61M |
| Net Income | $37.10M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $145.23M |
| P/E Ratio | 3.75 |
| EPS (TTM) | $0.16 |
| Exchange | OQX |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $96.39M |
| Sales | $255.61M |
| Income | $37.10M |
| Book/sh | $0.36 |
| Cash/sh | $0.25 |
| Employees | 65 |
Financial Ratios
| Quick Ratio | 1.54 |
| Current Ratio | 1.71 |
| Debt/Eq | 12.96 |
Returns & Margins
| ROA | 14.10% |
| ROE | 53.10% |
| Gross Margin | 21.66% |
| Operating Margin | 13.19% |
| Profit Margin | 14.51% |
Ownership
| Insider Ownership | 1.33% |
| Institutional Ownership | 0.05% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.90 |
| P/S | 0.57 |
| P/B | 1.64 |
Analyst Data
| Recommendation | none |
| Target Price | $3.00 |
Technical Indicators
| SMA20 | $0.66 |
| SMA50 | $0.68 |
| SMA200 | $0.52 |
| RSI | 37.14 |
| ATR | 0.0629 |
| Shares Float | 238.37M |
| Short Float | 9.40% |
| Short Ratio | 2.61 |
| Volatility | 1.18 |
| Rel Volume | 1.46 |
Performance History
| Week | -6.25% |
| Month | -21.05% |
| Quarter | -21.05% |
| 6 Months | +57.89% |
| YTD | +66.67% |
| Year | +33.33% |
| 3 Years | -50.00% |
| 5 Years | -90.80% |
| 10 Years | -96.31% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-03 | $0.60 | 682,100 |
| 2026-06-02 | $0.62 | 307,400 |
| 2026-06-01 | $0.63 | 352,600 |
| 2026-05-29 | $0.65 | 207,900 |
| 2026-05-28 | $0.66 | 260,600 |
| 2026-05-27 | $0.64 | 815,400 |
| 2026-05-26 | $0.63 | 552,100 |
| 2026-05-22 | $0.64 | 496,600 |
| 2026-05-21 | $0.68 | 445,800 |
| 2026-05-20 | $0.61 | 383,400 |
| 2026-05-19 | $0.61 | 609,700 |
| 2026-05-18 | $0.63 | 510,900 |
| 2026-05-15 | $0.68 | 168,500 |
| 2026-05-14 | $0.65 | 406,700 |
| 2026-05-13 | $0.69 | 418,100 |
| 2026-05-12 | $0.68 | 386,100 |
| 2026-05-11 | $0.65 | 830,200 |
| 2026-05-08 | $0.70 | 691,300 |
| 2026-05-07 | $0.74 | 423,300 |
| 2026-05-06 | $0.75 | 422,600 |
| 2026-05-05 | $0.76 | 399,800 |
| 2026-05-04 | $0.76 | 392,800 |
About Vaxart, Inc.
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
đ° Latest News
Vaxart, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-13T12:30:00Z
Vaxart Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-13T04:07:58Z
Vaxart Inc (VXRT) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...
GuruFocus.com âĸ 2026-03-13T03:08:08ZIs Vaxart's (VXRT) Conference Spotlight Reframing the Oral Vaccine Story or Just Polishing It?
Simply Wall St. âĸ 2026-02-28T03:12:32Z
Vaxart (VXRT) Valuation After New npj Vaccines Data On Oral Norovirus Candidate In Breastfeeding Women
Simply Wall St. âĸ 2026-01-27T21:07:32Z
The 3 Penny Stocks You Swore Youâd Never Buy (But Youâll Check Anyway)
MarketBeat âĸ 2026-01-18T14:40:00Z
Vaxart Inc (VXRT) Q3 2025 Earnings Call Highlights: Strategic Partnership and Revenue Surge ...
GuruFocus.com âĸ 2025-11-14T05:01:47Z
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-10T14:15:02Z
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates
Zacks âĸ 2025-11-06T22:20:02Z
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
Zacks âĸ 2025-08-13T21:25:02Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $28,700,000 | $7,379,000 | $107,000 | $892,000 |
| Operating Revenue | $28,700,000 | $7,379,000 | $107,000 | $892,000 |
| Expenses | ||||
| Interest Expense | $2,969,000 | $1,447,000 | $1,305,000 | $1,480,000 |
| Total Expenses | $94,993,000 | $90,726,000 | $110,440,000 | $70,639,000 |
| Other Income Expense | $31,000 | $-62,000 | $2,700,000 | $783,000 |
| Other Non Operating Income Expenses | $31,000 | $-62,000 | $6,954,000 | $3,789,000 |
| Net Non Operating Interest Income Expense | $-426,000 | $1,205,000 | $-58,000 | $-1,399,000 |
| Interest Expense Non Operating | $2,969,000 | $1,447,000 | $1,305,000 | $1,480,000 |
| Operating Expense | $94,993,000 | $90,726,000 | $110,440,000 | $70,639,000 |
| General And Administrative Expense | $20,780,000 | $22,584,000 | $29,386,000 | $21,890,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Net Interest Income | $-426,000 | $1,205,000 | $-58,000 | $-1,399,000 |
| Interest Income | $2,543,000 | $2,652,000 | $1,247,000 | $81,000 |
| Normalized Income | $-66,948,000 | $-82,465,000 | $-104,397,340 | $-68,275,620 |
| Net Income From Continuing And Discontinued Operation | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Total Operating Income As Reported | $-66,293,000 | $-83,347,000 | $-114,587,000 | $-72,752,000 |
| Net Income Common Stockholders | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Net Income | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Net Income Including Noncontrolling Interests | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Net Income Continuous Operations | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Pretax Income | $-66,688,000 | $-82,204,000 | $-107,691,000 | $-70,363,000 |
| Interest Income Non Operating | $2,543,000 | $2,652,000 | $1,247,000 | $81,000 |
| Operating Income | $-66,293,000 | $-83,347,000 | $-110,333,000 | $-69,747,000 |
| Special Income Charges | - | $0 | $-4,254,000 | $-3,005,000 |
| Per Share | ||||
| Diluted EPS | $-0.33 | $-0.57 | $-0.84 | $-0.58 |
| Basic EPS | $-0.33 | $-0.57 | $-0.84 | $-0.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-893,340 | $-811,620 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-54,869,000 | $-72,133,000 | $-96,327,000 | $-61,669,000 |
| Reconciled Depreciation | $8,850,000 | $8,624,000 | $5,805,000 | $4,208,000 |
| EBITDA (Bullshit earnings) | $-54,869,000 | $-72,133,000 | $-100,581,000 | $-64,675,000 |
| EBIT | $-63,719,000 | $-80,757,000 | $-106,386,000 | $-68,883,000 |
| Diluted Average Shares | $202,137,531 | $144,819,781 | $127,683,813 | $121,453,723 |
| Basic Average Shares | $202,137,531 | $144,819,781 | $127,683,813 | $121,453,723 |
| Diluted NI Availto Com Stockholders | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Tax Provision | $260,000 | $261,000 | $67,000 | $107,000 |
| Research And Development | $74,213,000 | $68,142,000 | $81,054,000 | $48,749,000 |
| Selling General And Administration | $20,780,000 | $22,584,000 | $29,386,000 | $21,890,000 |
| Other Gand A | $20,780,000 | $22,584,000 | $29,386,000 | $21,890,000 |
| Total Unusual Items | - | $0 | $-4,254,000 | $-3,006,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-4,254,000 | $-3,006,000 |
| Impairment Of Capital Assets | - | $0 | $4,254,000 | $3,005,000 |
| Gain On Sale Of Security | - | - | $-6,000 | $-1,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $50,860,000 | $49,008,000 | $101,069,000 | $172,399,000 |
| Total Assets | $166,389,000 | $91,830,000 | $153,847,000 | $221,168,000 |
| Total Non Current Assets | $98,129,000 | $46,294,000 | $54,396,000 | $52,001,000 |
| Other Non Current Assets | $839,000 | $926,000 | $3,568,000 | $890,000 |
| Non Current Prepaid Assets | $60,116,000 | $0 | - | - |
| Goodwill And Other Intangible Assets | $8,065,000 | $8,797,000 | $9,528,000 | $15,132,000 |
| Other Intangible Assets | $3,557,000 | $4,289,000 | $5,020,000 | $10,624,000 |
| Current Assets | $68,260,000 | $45,536,000 | $99,451,000 | $169,167,000 |
| Other Current Assets | $318,000 | $333,000 | $3,714,000 | $2,609,000 |
| Prepaid Assets | $4,250,000 | $2,482,000 | - | $2,609,000 |
| Receivables | $11,969,000 | $3,008,000 | $20,000 | $71,000 |
| Other Receivables | $6,208,000 | - | - | - |
| Accounts Receivable | $5,761,000 | $3,008,000 | $20,000 | $71,000 |
| Cash Cash Equivalents And Short Term Investments | $51,723,000 | $39,713,000 | $95,717,000 | $166,487,000 |
| Cash And Cash Equivalents | $25,229,000 | $34,755,000 | $46,013,000 | $143,745,000 |
| Cash Equivalents | $16,489,000 | $31,403,000 | $28,834,000 | $70,978,000 |
| Cash Financial | $8,740,000 | $3,352,000 | $15,179,000 | $72,767,000 |
| Restricted Cash | - | - | $2,000,000 | $0 |
| Debt | ||||
| Total Debt | $17,526,000 | $20,088,000 | $21,705,000 | $13,008,000 |
| Long Term Debt And Capital Lease Obligation | $14,449,000 | $17,385,000 | $19,477,000 | $11,997,000 |
| Current Debt And Capital Lease Obligation | $3,077,000 | $2,703,000 | $2,228,000 | $1,011,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $107,464,000 | $34,025,000 | $43,250,000 | $33,637,000 |
| Total Non Current Liabilities Net Minority Interest | $16,586,000 | $20,301,000 | $25,329,000 | $22,854,000 |
| Other Non Current Liabilities | $2,137,000 | $2,916,000 | $5,852,000 | $10,857,000 |
| Current Liabilities | $90,878,000 | $13,724,000 | $17,921,000 | $10,783,000 |
| Other Current Liabilities | $4,060,000 | $3,803,000 | $95,000 | $836,000 |
| Current Deferred Liabilities | $65,400,000 | $0 | $2,000,000 | $0 |
| Payables And Accrued Expenses | $13,254,000 | $2,642,000 | $10,486,000 | $6,150,000 |
| Payables | $6,963,000 | $1,584,000 | $5,514,000 | $3,872,000 |
| Accounts Payable | $6,963,000 | $1,584,000 | $5,514,000 | $3,872,000 |
| Equity | ||||
| Common Stock Equity | $58,925,000 | $57,805,000 | $110,597,000 | $187,531,000 |
| Total Equity Gross Minority Interest | $58,925,000 | $57,805,000 | $110,597,000 | $187,531,000 |
| Stockholders Equity | $58,925,000 | $57,805,000 | $110,597,000 | $187,531,000 |
| Gains Losses Not Affecting Retained Earnings | $4,000 | $-1,000 | $-299,000 | $-74,000 |
| Other Equity Adjustments | $4,000 | $-1,000 | $-299,000 | $-74,000 |
| Retained Earnings | $-476,522,000 | $-409,574,000 | $-327,109,000 | $-219,351,000 |
| Other | ||||
| Treasury Shares Number | $429,547 | $507,020 | - | - |
| Ordinary Shares Number | $227,774,275 | $153,452,833 | $134,199,429 | $125,594,393 |
| Share Issued | $228,203,822 | $153,959,853 | $134,199,429 | $125,594,393 |
| Tangible Book Value | $50,860,000 | $49,008,000 | $101,069,000 | $172,399,000 |
| Invested Capital | $58,925,000 | $57,805,000 | $110,597,000 | $187,531,000 |
| Working Capital | $-22,618,000 | $31,812,000 | $81,530,000 | $158,384,000 |
| Capital Lease Obligations | $17,526,000 | $20,088,000 | $21,705,000 | $13,008,000 |
| Total Capitalization | $58,925,000 | $57,805,000 | $110,597,000 | $187,531,000 |
| Treasury Stock | $350,000 | $366,000 | $0 | - |
| Additional Paid In Capital | $535,770,000 | $467,731,000 | $437,992,000 | $406,943,000 |
| Capital Stock | $23,000 | $15,000 | $13,000 | $13,000 |
| Common Stock | $23,000 | $15,000 | $13,000 | $13,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $14,449,000 | $17,385,000 | $19,477,000 | $11,997,000 |
| Current Deferred Revenue | $65,400,000 | $0 | $2,000,000 | $0 |
| Current Capital Lease Obligation | $3,077,000 | $2,703,000 | $2,228,000 | $1,011,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,087,000 | $4,576,000 | $3,112,000 | $2,786,000 |
| Current Accrued Expenses | $6,291,000 | $1,058,000 | $4,972,000 | $2,278,000 |
| Goodwill | $4,508,000 | $4,508,000 | $4,508,000 | $4,508,000 |
| Net PPE | $29,109,000 | $36,571,000 | $41,300,000 | $19,769,000 |
| Accumulated Depreciation | $-10,508,000 | $-6,831,000 | $-3,272,000 | $-1,305,000 |
| Gross PPE | $39,617,000 | $43,402,000 | $44,572,000 | $21,074,000 |
| Leases | $4,107,000 | $3,985,000 | $1,760,000 | $1,063,000 |
| Construction In Progress | $160,000 | $24,000 | $3,984,000 | $1,305,000 |
| Other Properties | $34,210,000 | $38,288,000 | $37,750,000 | $18,225,000 |
| Machinery Furniture Equipment | $1,140,000 | $1,105,000 | $1,078,000 | $481,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $26,494,000 | $4,958,000 | $49,704,000 | $22,742,000 |
| Investments And Advances | - | - | $0 | $16,210,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-45,318,000 | $-72,324,000 | $-104,380,000 | $-64,989,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-44,764,000 | $-70,453,000 | $-94,779,000 | $-59,832,000 |
| Cash Flow From Continuing Operating Activities | $-44,764,000 | $-70,453,000 | $-94,779,000 | $-59,832,000 |
| Operating Gains Losses | - | $55,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-554,000 | $-1,871,000 | $-9,601,000 | $-5,157,000 |
| Investing Cash Flow | $-21,324,000 | $43,952,000 | $-20,415,000 | $-49,097,000 |
| Cash Flow From Continuing Investing Activities | $-21,324,000 | $43,952,000 | $-20,415,000 | $-49,097,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $56,292,000 | $15,030,000 | $17,237,000 | $122,210,000 |
| Financing Cash Flow | $56,562,000 | $15,243,000 | $17,462,000 | $125,804,000 |
| Cash Flow From Continuing Financing Activities | $56,562,000 | $15,243,000 | $17,462,000 | $125,804,000 |
| Net Other Financing Charges | $-214,000 | $-366,000 | - | - |
| Net Common Stock Issuance | $56,292,000 | $15,030,000 | $17,237,000 | $122,210,000 |
| Common Stock Issuance | $56,292,000 | $15,030,000 | $17,237,000 | $122,210,000 |
| Other | ||||
| End Cash Position | $25,229,000 | $34,755,000 | $46,013,000 | $143,745,000 |
| Beginning Cash Position | $34,755,000 | $46,013,000 | $143,745,000 | $126,870,000 |
| Changes In Cash | $-9,526,000 | $-11,258,000 | $-97,732,000 | $16,875,000 |
| Proceeds From Stock Option Exercised | $484,000 | $579,000 | $225,000 | $3,594,000 |
| Net Investment Purchase And Sale | $-20,770,000 | $45,703,000 | $-10,814,000 | $-39,111,000 |
| Sale Of Investment | $43,500,000 | $73,200,000 | $44,200,000 | $5,700,000 |
| Purchase Of Investment | $-64,270,000 | $-27,497,000 | $-55,014,000 | $-44,811,000 |
| Net PPE Purchase And Sale | $-554,000 | $-1,751,000 | $-9,601,000 | $-5,157,000 |
| Sale Of PPE | $0 | $120,000 | $0 | $0 |
| Purchase Of PPE | $-554,000 | $-1,871,000 | $-9,601,000 | $-5,157,000 |
| Change In Working Capital | $3,262,000 | $-10,850,000 | $-4,698,000 | $-2,120,000 |
| Change In Other Working Capital | $65,400,000 | $-2,000,000 | $2,000,000 | - |
| Change In Payables And Accrued Expense | $8,605,000 | $-9,423,000 | $-2,966,000 | $-583,000 |
| Change In Accrued Expense | $3,332,000 | $-6,979,000 | $-3,323,000 | $-2,209,000 |
| Change In Payable | $5,273,000 | $-2,444,000 | $357,000 | $1,626,000 |
| Change In Account Payable | $5,273,000 | $-2,444,000 | $357,000 | $1,626,000 |
| Change In Prepaid Assets | $-61,782,000 | $3,561,000 | $-3,783,000 | $-1,800,000 |
| Change In Receivables | $-8,961,000 | $-2,988,000 | $51,000 | $263,000 |
| Changes In Account Receivables | $-2,753,000 | $-2,988,000 | $51,000 | $263,000 |
| Other Non Cash Items | $-668,000 | $710,000 | $-5,806,000 | $-3,407,000 |
| Stock Based Compensation | $11,501,000 | $14,132,000 | $13,587,000 | $8,867,000 |
| Amortization Of Securities | $-761,000 | $-659,000 | $-163,000 | $85,000 |
| Depreciation Amortization Depletion | $8,850,000 | $8,624,000 | $5,805,000 | $4,208,000 |
| Depreciation And Amortization | $8,850,000 | $8,624,000 | $5,805,000 | $4,208,000 |
| Gain Loss On Sale Of PPE | $0 | $55,000 | $0 | $0 |
| Net Income From Continuing Operations | $-66,948,000 | $-82,465,000 | $-107,758,000 | $-70,470,000 |
| Asset Impairment Charge | - | $0 | $4,254,000 | $3,005,000 |
| Net Business Purchase And Sale | - | - | $0 | $-4,829,000 |
| Purchase Of Business | - | - | $0 | $-4,829,000 |
| Repayment Of Debt | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
Fetched: 2026-02-02